Medical
-
Cornerstone Therapeutics has launched Bethkis tobramycin inhalation solution for the treatment of cystic fibrosis patients with P. aeruginosa infections in the US, the company said. According to Cornerstone, one dose of Bethkis contains 300 mg… Read more . . .
-
Canadian cardiovascular drug development company Milestone Pharmaceuticals has initiated a Phase 1 clinical trial of its lead product, MSP-2017 intranasal short-acting calcium channel antagonist for the treatment of paroxysmal supraventricular tachycardia (PSVT), the company announced.… Read more . . .
-
Florida-based Puget Technologies has announced that its subsidiary Cannabis Biotech has initiated a research project to develop an intranasal formulation of cannabinoids, saying that the “project is targeted towards those who desire the benefits of… Read more . . .
-
Insmed has announced that it anticipates discussions with the EMA by the end of 2013 regarding Arikace inhaled liposomal amikacin for the treatment of nontuberculous mycobacterial (NTM) lung disease and that it has already initiated… Read more . . .
-
Nephron Pharmaceuticals has announced a voluntary recall of ten lots of albuterol inhalation solution “as a precautionary measure, due to results from . . . internal monitoring processes.” The company says that it has not… Read more . . .
-
Diabetes research organization JDRF, along with Sansum Diabetes Research Institute, and the College of Engineering at University of California, Santa Barbara (UCSB) have announced positive results from a trial of an artificial pancreas used in… Read more . . .
-
Avanir Pharmaceuticals has published results of a pharmacokinetic study of its AVP-825 intranasal sumatriptan powder for the treatment of acute migraine. Avanir licensed AVP-825 from OptiNose in July 2013, and the powder is delivered using… Read more . . .
-
A Phase 3 trial of Flutiform fluticasone propionate/formoterol fumarate MDI for the treatment of COPD has been initiated, according Mundipharma. The 52-week randomized, double-blind EFFECT study compare Flutiform 250/10 μg and Flutiform 125/5 μg with… Read more . . .
-
Boehringer Ingelheim has presented new data from several Phase 3 studies of olodaterol for the treatment of COPD and from the TIOSPIR tiotropium Respimat study at the European Respiratory Society (ERS) Annual Congress 2013. Data… Read more . . .
-
Theravance has announced that a dose-ranging 7-day Phase 2b study of TD‑4208 inhalation solution, an investigational long-acting muscarinic antagonist (LAMA) for the treatment of COPD, met its primary endpoints for all six doses. TD-4208 showed… Read more . . .

Upcoming Events
Sponsored by Intertek
Want information about upcoming OINDP-related events delivered directly to your inbox? click here
December 9-December 11: DDL 2026, Edinburgh, Scotland
April 27-30: RDD Europe 2027, Antibes, France
May 12-13: USP Joint Workshop: Quality and Product Performance Testing of Orally Inhaled and Nasal Drug Products, Rockville, MD, USA
May 30-June 2: ISAM Congress 2027, Dublin, Ireland
June 23: SMI London, London, UK

